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Abstract 
Piroxicam is a NSAID that is widely used in the treatment of joint 
pain and osteoarthritis. The objectives of the study were to modify 
and validate HPLC method so as to obtain an accurate, sensitive 
and precise method to quantify piroxicam concentrations without 
interference from the other ingredients presence in the 
formulation. The method published by Owen et al. was adapted 
and modified to suit the above requirements. The modification 
was carried out on the mobile phase as the mobile phase used by 
the authors was not able to separate the drug peak from the 
interference of the formulation excipients. The modified mobile 
phase consisted of 5 mM of disodium hydrogen phosphate  
adjusted to pH 3 with concentrated ortho phosphoric acid, 
methanol, acetonitrile and glacial acetic acid at ratios of  
27:20:52:1 respectively. The method was validated and found to 
be specific, precise, accurate and reproducible even when run at 
different times of the same day or on different times on different 
days. The limit of detection and quantification were determined to 
be 0.035 µg/ml and 0.0625 µg/ml respectively. It could be 
concluded that this method could be used to determine piroxicam 
concentration in the samples collected from in vitro study of 
permeability through the synthetic membrane and excised rat 
skin. 
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Modification. 
 
Introduction 
Piroxicam is a NSAID that is widely used in the 
treatment of joint pain and osteoarthritis. Many 
HPLC method were reported in the previous 
literature to measure piroxicam in plasma 
samples [2,3]. To detect piroxicam being 
transferred through cellulose membrane and skin 
in in- vitro franz diffusion cell, a method of high 
sensitivity is required. Because it is expected that 
piroxicam quantity diffused into the receptor cell 
is very low. The method published by Owen et al. 
(1987) was adapted and modified to suit the 
above requirements. The modification was 
carried out on the mobile phase as the mobile 
phase used by the authors was not able to 
separate the drug peak from the interference of 
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the formulation excipients. These excipients are 
the constituents of nano-cream. These are palm 
oil esters, Tween 80, Span 20 and phosphate 
buffer as external phase. Additionally, the 
interference of constitutes that might be leached 
from the skin during the diffusion process.   
The objectives of the study were to modify and 
validate HPLC method so as to obtain an 
accurate, sensitive and precise method to quantify 
piroxicam concentrations without interference 
from the other ingredients presented in the 
formulation and other leachable skin constituents.   
 
Materials and Methods 
Materials 
Disodium hydrogen phosphate was supplied by R 
& M Chemicals (UK). Orthophosphoric acid and 
glacial acetic acid were supplied by BDH (UK). 
Methanol and acetonitrile (HPLC grade) were 
purchased from J.T. Baker (USA). Nylon 
membrane filters (0.45µm pore size) was 
purchased from Whatman International (UK).   
 
Methods  
Instrumentation 
The Shimadzu HPLC system (SCL-10A) 
consisted of an isocratic pump (Shimadzu Co, 
Japan, model LC-10-ATVP), an auto sampler 
(Shimadzu, Japan, model SIL-10AD) and a 
model SPD-10AV UV-VIS detector. The reverse 
phase chromatography was performed with an 
analytical stainless steel column 
(150 mm × 2.0 mm), containing C18 stationary 
phase 5-μm (thermo, Germany) protected with a 
SecurityGuard™ cartridge system (Phenomenex) 
and a 0.45-μm in-line filter. 
 
Chromatographic conditions 
The mobile phase consisted of 5 mM of disodium 
hydrogen phosphate  adjusted to pH 3 with 
concentrated ortho phosphoric acid, methanol, 
acetonitrile and glacial acetic acid at ratios of  
27:20:52:1 respectively. The mobile phase was 
filtered through 0.45 µm nylon membrane filter 
and degassed prior to use. The mobile phase used 
by Owen et al. (1987) was a mixture of 0.03% 
phosphoric acid (pH 2.5):acetonitrile at a ratio of 
55:45. Samples were placed in the auto-sampler. 
20 µg was injected and eluted through the 
separation column at a flow rate of 1 ml/min, at 
room temperature and detected by UV-VIS at a 
wavelength of 350 nm. 
 
Preparation of stock and working standard 
solutions 
Piroxicam stock solution of 1 mg/ml was 
prepared by dissolving appropriate weight of 
piroxicam in acetonitrile and stored at 4 °C. The 
stock solution prepared was consequently diluted 
with acetonitrile to obtain working standard 
solution of 25 µg/ml when needed. 
 
Preparation of calibration standards 
The working standard solution of piroxicam was 
serially diluted with the mobile phase to produce 
concentrations of 0.0625, 0.125, 0.25, 0.5, 1 and 
2 µg/ml.  
 
Method validation 
Linearity 
The linearity of standard curve for the 
concentrations range 0.0625-2 µg/ml of 
piroxicam was determined by using freshly 
prepared calibration standard samples. Six 
linearity curves were analysed. Each calibration 
curve consisted of six concentrations as in 2.2.4. 
The samples were quantified by measuring the 
peak height corresponding to piroxicam. The 
calibration curve was a plot of piroxicam 
concentration in calibration standard against the 
corresponding piroxicam peak height of HPLC 
chromatograms. A correlation of more than 0.999 
was recommended for all the calibrated curves. 
 
Specificity 
Samples of blank formulation of E16 which 
contains all ingredients but without piroxicam 
and samples of E16 containing piroxicam were 
analysed by the same method. Weighed amount 
of the samples were dissolved in the mobile 
phase and then diluted with the mobile phase. 
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The samples were analysed to quantify the 
strength of formulation E16 prepared and assess 
any interference by other ingredients of the 
formulation at the retention time of piroxicam. 
 
Precision and accuracy 
The precision and accuracy of the mean were 
determined for the inter-day and intra-day 
analysis to validate the accuracy and precision of 
the method. For inter-day validation, six sets of 
samples at six different concentrations were 
evaluated for six different days by assessing the 
precision and accuracy. For intra-day validation, 
six sets of samples at six different concentrations 
were analysed on the same day and evaluated by 
assessing the precision and accuracy. Precision 
must not be above ±15% for calibrated 
concentrations level and not more than ±20% for 
lowest value in the calibration curve [4]. 
Similarly, accuracy of the mean should not be 
more than ±15% at all concentrations levels and 
not more than ±20% for lowest value in the 
calibration curve.  
Precision was calculated according to the 
following equation: 
(Standard deviation/ mean) ×100  
Accuracy was measured by the following 
equation: 
(Nominal concentration/ actual concentration)×100  
 
Limit of detection and limit of quantification 
The limit of detection was defined as the 
concentration that exhibit HPLC peak 
measurement of three times the level of baseline 
noise, in other words, at a signal to noise ratio of 
3:1. The lowest concentration defined as the limit 
of quantification must have a peak height value 
of at least equal to five times the baseline noise.  
 
Results and Discussion  
Linearity 
The calibration curve (Fig. 1.1) exhibited an 
excellent linearity over the concentration range of 
62.5-2000 ng/ml. The mean linear regression 
equation from six replicated calibration curve 
were y = 2031.1x - 1.495, with a correlation 
coefficient of 0.9998.  
 
Specificity 
The HPLC chromatogram showed that there was 
no interference of any of the formulae ingredients 
at the retention time of piroxicam at 4.7 minutes 
(Fig. 1.2a and 1.2b). 
 
Precision and accuracy 
Table 1.1 shows that the intra-day accuracy 
values are ranged between 85.06-101.94% with a 
precision of 1.70-6.15%. Similarly, Table 1.2 
shows that the inter-day accuracy ranged between 
86.50-107.76% with a precision of 0.41-5.88%. 
The precision and accuracy of all concentration 
values were less than ±15%.  The results showed 
that the method is reproducible and precise within 
and between the analytical runs during the same 
day and on different day.  
Table 1.1: Intra-day accuracy and precision 
results of piroxicam. All data are presented as 
mean±SD, (N=6). 
 
Nominal 
concentrati
on 
(μg/ml) 
Actual 
concentrati
on 
(μg/ml) 
Accura
cy 
(%) 
Precisio
n 
(%) 
0.0625 0.0718 (0.0012) 85.06 1.70 
0.1250 0.1326 (0.0082) 93.91 6.15 
0.2500 0.2475 (0.0134) 100.99 5.43 
0.5000 0.4903 (0.0086) 101.94 1.75 
1.0000 0.9865 (0.0272) 101.35 2.75 
2.0000 2.0087 (0.0576) 99.57 2.87 
Values in parenthesis are the standard deviations 
 
Limit of detection and limit of quantification 
Based on the peak height of 3 times the noise 
level, the limit of detection was 0.035 μg/ml and 
based on the peak height of 5 times the noise 
level, limit of quantification was 0.0625 μg/ml.  
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Table 1.2: Inter-day accuracy and precision results of 
piroxicam. All data are presented as mean±SD, (N=6).  
 
Nominal 
concentration 
(μg/ml) 
Actual 
concentration 
(μg/ml) 
Accuracy 
(% ) 
Precisio
n 
(%) 
0.0625 0.0709 (0.0021) 86.51 2.93 
0.1250 0.1390 (0.0082) 88.78 5.88 
0.2500 0.2306 (0.0026) 107.76 1.11 
0.5000 0.4878 (0.0020) 102.43 0.41 
1.0000 0.9955 (0.0282) 100.45 2.84 
2.0000 2.0067 (0.0132) 99.67 0.66 
Values in parenthesis are the standard deviations 
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